Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.
Company profile
Ticker
GMAB, GNMSF
Exchange
Website
CEO
Jan van de Winkel
Employees
Location
Industry (SIC)
SEC CIK
GMAB stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
22 Apr 24
6-K
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
16 Apr 24
6-K
Current report (foreign)
15 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
3 Apr 24
6-K
Current report (foreign)
2 Apr 24
6-K
Current report (foreign)
25 Mar 24
6-K
Current report (foreign)
21 Mar 24
6-K
Completion of share buy-back program
18 Mar 24
6-K
Genmab Announces Initiation of Share Buy-Back Program
15 Mar 24
Latest ownership filings
144
Notice of proposed sale of securities
1 Mar 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
BlackRock Inc.
2 Feb 24
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
SC 13G/A
BlackRock Inc.
3 Feb 22
SC 13G/A
BlackRock Inc.
29 Jan 21
SC 13G
Beneficial ownership report
7 Feb 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
7.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 226 |
Opened positions | 44 |
Closed positions | 21 |
Increased positions | 92 |
Reduced positions | 54 |
13F shares | Current |
---|---|
Total value | 1.66 tn |
Total shares | 47.11 mm |
Total puts | 56.30 k |
Total calls | 36.70 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Alliancebernstein | 9.52 mm | $335.60 bn |
BLK Blackrock | 4.82 mm | $169.91 bn |
Capital International Investors | 4.32 mm | $152.57 bn |
MCQEF Macquarie | 3.25 mm | $114.62 bn |
Harding Loevner | 3.20 mm | $113.01 bn |
Wellington Management | 2.43 mm | $85.54 bn |
1832 Asset Management | 2.24 mm | $79.13 bn |
Renaissance Technologies | 1.17 mm | $41.51 bn |
MS Morgan Stanley | 1.10 mm | $38.82 bn |
First Trust Advisors | 1.09 mm | $38.61 bn |
News
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
8 Apr 24
HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
4 Apr 24
Genmab To Acquire ProfoundBio For $1.8B Cash, Enhancing And Expanding Its Oncology Portfolio
3 Apr 24
HC Wainwright & Co. Maintains Buy on Genmab, Maintains $50 Price Target
27 Mar 24
Morgan Stanley Maintains Underweight on Genmab, Maintains $32 Price Target
26 Mar 24
Press releases
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
3 Apr 24
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
27 Feb 24
Genmab Announces Initiation of Share Buy-Back Program
14 Feb 24
Genmab Publishes 2023 Annual Report
14 Feb 24
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
2 Feb 24